Who Paid My Doc
Adhansia XR
Drug Prescription Stimulant
NDC 72912-525-30
General payments
$776,729
Research payments
$6,968,285
Through program year 2023, $776,729 in general payments and $6,968,285 in research payments were reported against Adhansia XR (Prescription Stimulant).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
9 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $91,785 | 4 |
| 2022 | General | $28,520 | 7 |
| 2022 | Research | $1,515,271 | 247 |
| 2021 | General | $327,195 | 13,926 |
| 2021 | Research | $1,486,307 | 302 |
| 2020 | General | $170,144 | 7,658 |
| 2020 | Research | $554,330 | 42 |
| 2019 | General | $250,870 | 4,301 |
| 2019 | Research | $3,320,592 | 100 |
Breakdown
The top 5 of 6 recipients; each share is of general payments naming this product in 2022.
Each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.
The top 5 of 6 states; each share is of general payments naming this product in 2022 where a state was reported.
Records
25,892 general · 695 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.